drugset / Trial / NCT02418884

The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus

NCT02418884 ↗

Phase 4 Unknown 122 enrolled Sir Run Run Shaw Hospital
NaSingle-groupOpen-labelPrevention

Summary

This study is designed to validate the hypothesis that the treatment of rosuvastatin could increase the score of Calcification of Coronary artery(CAC) density in coronary artery disease(CAD) patients with diabetes mellitus.CAD patients with diabetes who confirmed CAC will receive rosuvastatin (20mg/d) therapy for 24 months.

Timeline

Start
2015-04
Primary completion
2018-03
Completion
2018-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 20 mg —